Skip to content
Search

Latest Stories

NPA discusses 'hub and spoke' with competition watchdog

The National Pharmacy Association has held a meeting with senior officials at the Competition and Markets Authority (CMA) to discuss the potential impact of hub and spoke dispensing on community pharmacy.

The Association has persistently calling on the competition watchdog to look into hub and spoke dispensing to ensure fairness.


A public consultation is currently under way on government plans to enable ‘inter-company hub and spoke’, where a pharmacy outsources elements of its dispensing to a third party, since the Medicines and Medical Devices Act became law in 2021 which paved the way for regulations to legalise the model.

The NPA told senior officials at CMA that a fair and competitive market for hubs would be essential to avoid unintended consequences such as price rises and poor service.

It asked the competition watchdog to consider the matter prior to commencement of the policy and also to commit to a post implementation market review.

NPA vice chair, Nick Kaye, who attended the meeting, said: “It is highly likely only a few companies in the market will be able to provide fully comprehensive external hub dispensing services to pharmacies, at least initially. This would put pharmacies in a weak position as customers and might also lead to a rise in medicines prices for the NHS, the taxpayer and the public.

“If pharmacies are truly to benefit from hub and spoke dispensing, there needs to be a dynamic and competitive market in which hubs compete for the custom of pharmacies on the basis of quality service and price.

“Significant capital investment is necessary to set up a hub as well as ongoing costs. This, together with the current restrictive wholesaler distribution arrangements, presents a formidable barrier to market entry.”

More For You

Imported dengue reach record high, warns UKSHA

Most dengue cases were linked to travel to Southern and South-Eastern Asia.

Getty Images

Imported dengue cases hit record high – Consult your pharmacist before you travel

The UK Health Security Agency (UKSHA) has warned that imported dengue cases in England, Wales, and Northern Ireland (EWNI) have reached their highest level since dengue surveillance began in 2009.

New data from the agency reveals that 904 dengue cases were reported among returning travellers in these countries in 2024, a sharp increase from 631 in 2023.

Keep ReadingShow less
Henry Gregg named as new NPA chief executive

Henry Gregg (left) with Sir Chris Whitty

Pic credit: Henry Gregg/X

Henry Gregg named as new NPA chief executive

The National Pharmacy Association (NPA) has announced Henry Gregg will be the organisation’s new chief executive from May.

Gregg, who is currently director of external affairs at Asthma + Lung UK, replaces Paul Rees who departed in January.

Keep ReadingShow less
Kelso Pharma continues expansion with £140M funding boost

Kelso Pharma will use the funds to support further acquisitions and expand in the UK and Europe.

Getty Images

Kelso Pharma secures over £140m of acquisition funding

Kelso Pharma has secured more than £140 million of acquisition funding to support its expansion in the UK and across Europe.

The specialty pharmaceuticals business today (27) confirmed that a proportion of the funding was used for its acquisition of ALTURiX last month, a deal that doubled the size of the company’s UK business.

Keep ReadingShow less
Community pharmacist accessing GP Connect Access Record on Cegedim Rx platform

GP Connect Access Record will make a patient’s relevant medical information available to pharmacy.

Getty Images

Cegedim Rx activates GP Connect Access Record

Community pharmacy IT supplier Cegedim Rx has made GP Connect Access Record functionality available across its clinical services platform, providing registered pharmacy professionals with enhanced access to patient medical information.

The new feature, now live on Cegedim Rx’s Pharmacy Services platform, allows community pharmacies to retrieve relevant medical data when delivering NHS clinical services.

Keep ReadingShow less
Prepayment certificates helped patients avoid £837M in prescription fees, NHSBSA analysis reveals

Patients who purchase two prescriptions per month could save more than £110 annually with a 12-month PPC.

Getty Images

Prepayment certificates helped patients avoid £837M in prescription fees, NHSBSA analysis reveals

The NHS Business Services Authority (NHSBSA) has published a new experimental analysis, estimating patient savings achieved from prescription prepayment certificates (PPCs), including Hormone Replacement Therapy (HRT) PPCs.

The report revealed that the number of Prescription Prepayment Certificates (PPCs) purchased has risen consistently over the past five years, with 3.3 million patients receiving NHS prescriptions under a PPC exemption in 2023/2024.

Keep ReadingShow less